Circulating tumor cells as therapy-related biomarkers in cancer patients.
Standard
Circulating tumor cells as therapy-related biomarkers in cancer patients. / Gorges, Tobias; Pantel, Klaus.
in: CANCER IMMUNOL IMMUN, Jahrgang 62, Nr. 5, 5, 2013, S. 931-939.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating tumor cells as therapy-related biomarkers in cancer patients.
AU - Gorges, Tobias
AU - Pantel, Klaus
PY - 2013
Y1 - 2013
N2 - Carcinomas (tumors of epithelial origin) are responsible for most of all new cancers in the industrialized countries. Due to the high mortality rate caused by the metastatic spread of aggressive cancer cells, there is an urgent demand in finding new biomarkers, which should detect early formation of metastases and monitor efficacy of systemic adjuvant therapy in a timely manner. It has been considered that the molecular analysis of cells which are shed from tumors into the blood system (circulating tumor cells (CTCs)) might provide new insights for the clinical management of cancer, probably far earlier than using traditional high-resolution imaging technologies. Clinical trials indicated that CTCs can be deployed for diagnostic, monitoring, and prognostic purposes. Furthermore, these cells are discussed to be suitable as predictive markers. In any case, identification of CTCs requires innovative and challenging technologies as detection methods should be specific, sensitive, standardized, and highly reproducible. Although many different approaches have been developed until now, only the CellSearch™ method has been cleared by the American Food and Drug Administration. Although the detection of CTCs has already shown to have a prognostic impact in many tumor entities including breast, prostate, lung and colon cancer, ongoing and future studies are aimed to explore whether CTCs can be used for an individual therapy decision making including novel immunotherapeutic approaches. This review discusses (1) different detection strategies for CTCs, (2) their clinical impact, and (3) the potential use of CTCs guiding the treatment of individual cancer patients.
AB - Carcinomas (tumors of epithelial origin) are responsible for most of all new cancers in the industrialized countries. Due to the high mortality rate caused by the metastatic spread of aggressive cancer cells, there is an urgent demand in finding new biomarkers, which should detect early formation of metastases and monitor efficacy of systemic adjuvant therapy in a timely manner. It has been considered that the molecular analysis of cells which are shed from tumors into the blood system (circulating tumor cells (CTCs)) might provide new insights for the clinical management of cancer, probably far earlier than using traditional high-resolution imaging technologies. Clinical trials indicated that CTCs can be deployed for diagnostic, monitoring, and prognostic purposes. Furthermore, these cells are discussed to be suitable as predictive markers. In any case, identification of CTCs requires innovative and challenging technologies as detection methods should be specific, sensitive, standardized, and highly reproducible. Although many different approaches have been developed until now, only the CellSearch™ method has been cleared by the American Food and Drug Administration. Although the detection of CTCs has already shown to have a prognostic impact in many tumor entities including breast, prostate, lung and colon cancer, ongoing and future studies are aimed to explore whether CTCs can be used for an individual therapy decision making including novel immunotherapeutic approaches. This review discusses (1) different detection strategies for CTCs, (2) their clinical impact, and (3) the potential use of CTCs guiding the treatment of individual cancer patients.
KW - Humans
KW - Prognosis
KW - United States
KW - Recurrence
KW - Neoplasm Metastasis
KW - Polymerase Chain Reaction
KW - Neoplastic Cells, Circulating/pathology
KW - Epithelial-Mesenchymal Transition
KW - Tumor Markers, Biological/metabolism
KW - Biopsy/methods
KW - Leukocytes/cytology
KW - Carcinoma/blood/diagnosis
KW - Medical Oncology/methods
KW - Neoplasms/blood/immunology/therapy
KW - United States Food and Drug Administration
KW - Humans
KW - Prognosis
KW - United States
KW - Recurrence
KW - Neoplasm Metastasis
KW - Polymerase Chain Reaction
KW - Neoplastic Cells, Circulating/pathology
KW - Epithelial-Mesenchymal Transition
KW - Tumor Markers, Biological/metabolism
KW - Biopsy/methods
KW - Leukocytes/cytology
KW - Carcinoma/blood/diagnosis
KW - Medical Oncology/methods
KW - Neoplasms/blood/immunology/therapy
KW - United States Food and Drug Administration
M3 - SCORING: Journal article
VL - 62
SP - 931
EP - 939
JO - CANCER IMMUNOL IMMUN
JF - CANCER IMMUNOL IMMUN
SN - 0340-7004
IS - 5
M1 - 5
ER -
